Online inquiry

IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13856MR)

This product GTTS-WQ13856MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13856MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13864MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ6288MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ1651MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ7022MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ8927MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ6588MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ739MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ11023MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW